fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

MHRA (UK) approves seladelpar (Livdelzi) to treat primary biliary cholangitis – CymaBay

Written by | 12 Feb 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has  16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called… read more.

Positive CHMP opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma – BMS

Written by | 6 Feb 2025

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the  EMA has recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the… read more.

A common antihistamine shows promise in treating liver complications of a rare disease complication

Written by | 23 Jan 2025

A common antihistamine may offer hope for patients with a rare genetic disease that can lead to severe liver damage and ultimately require transplantation, according to new research… read more.

Combined health screening can detect liver damage in diabetic patients

Written by | 2 Jan 2025

New research from Karolinska Institutet in Sweden highlights the potential benefits of screening people with type 2 diabetes for liver damage at the same time as they undergo… read more.

Combined screening can detect liver damage in diabetes patients

Written by | 20 Dec 2024

New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening… read more.

Beer-only drinkers’ diets are worse than wine drinkers

Written by | 24 Nov 2024

Beer drinkers have lower-quality diets, are less active, and are more likely to smoke cigarettes than people who drink wine, liquor, or a combination, according to a study… read more.

Aligos Therapeutics announces positive data on chronic hepatitis B and MASH treatments at AASLD 2024

Written by | 22 Nov 2024

Aligos Therapeutics, Inc. a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from… read more.

Late breaking data for Iqirvo (elafibranor) from interim analysis of Phase III ELATIVE study for Primary Biliary Cholangitis at AASLD meeting – Ipsen

Written by | 20 Nov 2024

Ipsen announced  late-breaking data for Iqirvo (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American… read more.

GSK showcases advances in chronic Hepatitis B and Cholestatic Pruritus research at AASLD liver meeting 2024

Written by | 16 Nov 2024

GSK plc (will present 12 abstracts at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2024, taking place in San Diego, CA from 15-19… read more.

AASLD 2024: Mirum presents breakthrough data on Maralixibat and Volixibat for cholestatic liver diseases

Written by | 15 Nov 2024

Mirum Pharmaceuticals, Inc. (announced that it will present data at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting®, taking place November 15-19, 2024,… read more.

2024 AASLD Liver Meeting to feature Madrigal Pharmaceuticals’ new Insights on Resmetirom for NASH

Written by | 2 Nov 2024

Madrigal Pharmaceuticals, Inc. a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH),  announced multiple resmetirom data presentations at the upcoming American Association… read more.

DURECT Corporation to highlight new data on Larsucosterol for alcohol-associated hepatitis at The Liver Meeting 2024

Written by | 21 Oct 2024

DURECT Corporation a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.